Gilles Divita
Chief Executive Officer Divincell
Dr. Divita Gilles is the Founder and CEO of DIVINCELL SAS, a biopharmaceutical nanomedicine start-up pioneering novel drug delivery technologies for the treatment of cancer and genetic diseases. With over 25 years of experience in drug delivery systems, peptide/protein drugs, and oligonucleotide therapeutics, he is widely recognized as the pioneer of the non-covalent cell-penetrating peptide-based delivery strategy, with landmark publications in Nature Biotechnology, Science, and Nucleic Acids Research.
He has authored more than 180 peer-reviewed articles and holds 15 patents. His work has introduced the concept of multifunctional nanoparticles for efficient targeted delivery of drugs and bioprobes, enabling new therapeutic strategies across oncology, genetic disorders, and diagnostics.
Dr. Gilles earned his Ph.D. in Biochemistry/Biophysics from the University of Lyon, France, and has held research positions at the Max Planck Institute (Germany), The Scripps Research Institute (USA), and the CNRS in France, where he served as Research Director and head of the Chemical Biology & Nanotechnology for Therapeutics team until 2017.
Seminars
- Exploring advances in organ-specific mRNA delivery, including inhalation, intranasal, and systemic routes
- Examining emerging lipid and polymer systems designed for non-hepatic targeting
- Review case studies and clinical updates from respiratory and extrahepatic mRNA programs
